An interventional study of Paired associative stimulation (with eXimia magnetic stimulator and Dantec Keypoint® electroneuromyography device) in Spinal Cord Injuries and Spinal Cord Diseases, sponsored by Helsinki University Central Hospital. Completed at 1 site in Finland. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-05-13.
Sponsored by Helsinki University Central Hospital · Not applicable, Interventional, and Treatment
The investigators have recently shown in incomplete SCI patients that long-term paired associative stimulation is capable of restoring voluntary control over some paralyzed muscles and enhancing motor output in the weak muscles (1,2). In this study, the investigators will administer long-term paired associative stimulation to patients with incomplete cervical level SCI and investigate its effectiveness for lower extremity rehabilitation.
Exclusion Criteria:
The intervention is given to peripheral nerve - motor cortex pairs selected by the investigator.
Device: Paired associative stimulation (with eXimia magnetic stimulator and Dantec Keypoint® electroneuromyography device)
Paired associative stimulation (PAS) administered several times per week for 8 weeks to lower limbs. PAS comprises transcranial magnetic stimulation (eXimia magnetic stimulator, Nexstim Ltd, Helsinki, Finland) and peripheral nerve stimulation (given with Dantec Keypoint® electroneuromyography device (Natus Medical Incorporated, Pleasanton, CA, USA)).
Daniels and Worthingham's Muscle Testing
Leg muscle stenght is evaluated on 0-5 scale (0=no movement, 5=normal)
Time frame: 2 days after the last stimulation session
Daniels and Worthingham's Muscle Testing
leg muscles are evaluated on 0-5 scale
Time frame: 1 month after the last stimulation session
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Helsinki University Central Hospital